natgillin/translations-raw huggingface dataset:
In a fifth aspect of the eighth disclosure, the crystallizing occurs at a temperature that ranges from about -10°C to about +40°C and all temperature values in between. 
Postupak iz patentnog zahtjeva 1, u kome se kristalizacija događa na temperaturi koja je u opsegu od -10"C€ do +40"C.
The salt of claim 8, characterized by 2-theta diffraction angle absorption bands obtained form an X-ray powder diffraction pattern of the same or essentially the same as 24.91, 18.46 and 17.76 degrees. 
Sol prema zahtjevu 8, naznačena time što su 2-theta kutovi difrakcije apsorpcijskih vrpci, koje su dobivene rendgenskom difrakcijom praška, jednaki ili u biti jednaki 24.91, 18.46 1 17.76 stupnjeva.
In a further embodiment the invention also relates to use of a compound of the invention as the free base or a salt thereof for the preparation of a pharmaceutical composition for the treatment of general anxiety disorder. 
U jednom daljnjem obliku spoj se takoder odnosi na korištenje spoja izuma kao slobodne baze ili njezine soli za pripravak farmaceutskog sastava kod liječenja općih smetnji anksioznosti.
Two types of kinins receptors exist, B1 and B2. 
Postoje dva tipa kiniskih receptora, BI i B2.
Underground waste container device (1) according to claim 9 or 10, wherein said synchronization mechanism (41) comprises a synchronization linkage or a synchronization gear (42). 
Uređaj s podzemnim kontejnerom za otpad (1) prema zahtjevu 9 ili 10, pri čemu se navedeni mehanizam za sinkroniziranje (41) sastoji od sinkronizacijskog lančanog spoja ili zupčanika (42).
affixing a cover layer (62) to the gel layer; characterised in that the gel material comprises a gel having a hardness in the range of about 0.5 kPa to about 50 kPa when measured according to the method of ISO 3386-1, and wherein the gel material exhibits a hysteresis of about 15% to about 80%. 
- - pričvršćivanje pokrovnog sloja (62) za sloj gela; naznačen time što gel materijal sadrži gel koji ima čvrstoću u opsegu od oko 0,5 kPa do oko 50 kPa kada je mjerenje izvedeno prema postupku ISO 3386-1, i pri čemu gel materijal ispoljava histerezu od oko 15% do oko
A polypeptide comprising an N-terminal portion and a C-terminal portion, wherein said N-terminal portion comprises the signature sequence QGP[P or L] and the amino acid sequence of said C-terminal portion is at least 70% identical to SEQ ID NO: 1. 
Polipeptid koji ima N-terminalni dio i C-terminalni dio, naznačen time da N-terminalni dio sadrži potpisnu sekvencu QGPIP ili L] i sekvenca amino kiseline, navedenog C-terminalnog dijela je u barem 70 % identična sa SEQ ID NO: 1.
All of them produced dose-dependent inhibitory effect, which correlated well with the clinical antispastic efficacy of the muscle relaxant drugs. 
Svi ti lijekovi uzrokuju inhibitorski učinak ovisan o dozi, koji dobro korelira s kliničkom antispastičkom učinkovitošću lijekova za relaksaciju mišića.
Preferred polypeptides of interest are of human origin, and more preferably, the proteins of interest are therapeutic proteins. 
Preferirani proteini od interesa humanog su podrijetla, i što je još više preporučljivo, proteini od interesa su terapeutski proteini.
The combined extract was dried (sodium sulfate), filtered, and concentrated in vacuo to give intermediate 23 (0.235 g, 5.2% over two steps) as a brown solid. 
Kombinirani ekstrakti su sušeni (natrij sulfat), filtrirani i koncentrirani in vacuo da bi se dobio Intermedijer 23 (0.235 g, 5.2% kroz dva koraka) kao smeđe čvrsta supstanca.
The compound according to claim 4 having the formula Ib-1j: and pharmaceutically acceptable salts, solvates and prodrugs thereof, wherein 
je definiran kao u gore navedenom patentnom zahtjevu 5. Spoj sukladno patentnom zahtjevu 4 koje ima formulu Ib-1j:
The method according to claim 1, in which the pharmaceutically acceptable salt of L-carnitine is selected from the group consisting of chloride, bromide, orotate, aspartate, acid aspartate, acid citrate, magnesium citrate, phosphate, acid phosphate, fumarate and acid fumarate, magnesium fumarate, lactate, maleate and acid maleate, oxalate, acid oxalate, pamoate, acid pamoate, sulphate, acid sulphate, glucose phosphate, tartrate and acid tartrate, glycerolphosphate, mucate, magnesium tartrate, 2-amino ethanesulphonate, magnesium 2-amino ethanesulphonate, methanesulphonate, choline tartrate, trichloroacetate, and trifluoroacetate. 
Upotreba u skladu s patentnim zahtjevom 1, naznačena time što se farmaceutski prihvatljivu sol L-karnitina bira iz skupine koju čine klorid, bromid, ortat, aspartat, kiseli aspartat, kiseli citrat, magnezijev citrat, fosfat, kiseli fosfat, fumarat i kiseli fumarat, magnezijev fumarat, laktat, maleat i kiseli maleat, oksalat, kiseli oksalat, pamoat, kiseli pamoat, sulfat, kiseli sulfat, glukozni fosfat, tartarat i kiseli tartarat, glicerofosfat, mukat, magnezijev tartarat, 2-aminoetansulfonat, magnezijev 2-aminoetansulfonat, metansulfonat, kolin-tartarat, trikloracetat, te trifluoracetat.
The method of claim 13, wherein the at least one attenuated Salmonella or the at least one inactivated Salmonella of the Salmonella D group is Salmonella Enteritidis. 
Uporaba prema zahtjevu 12, naznačena time, da najmanje jedna atenuirana Salmonella ili najmanje jedna neaktivirana Salmonella od Salmonella skupine D je Salmonella Enteritidis.
The antibody or a functional fragment of the antibody according to claim 14, characterized in that the antibody is an antibody produced by hybridoma #32A1 (FERM BP-10999). 
Monoklonsko antitijelo ili njegov funkcionalni fragment, sukladno sa bilo kojim od zahtjeva 1-7, karakteriziranih time da je antitijelo antitijelo proizvedeno od hibridoma stanica FERM BP-10999 (#32A1) ili hibridoma stanica
The transdermal delivery device of any one of the preceding claims, further comprising an adhesive layer adjacent to, and in contact with, the polymer matrix layer and permeable to the opioid agonist. 
Sredstvo za transdermalno davanje prema zahtjevu 14, naznačeno time da nadalje sadrži adhezivni sloj koji se nalazi pored i koji je u kontaktu s matričnim slojem i koji je propustan za terapeutski aktivni agens.
pretreating the biomass composition comprising cellulose, hemicellulose, and/or lignocellulose to produce a pretreated biomass composition comprising solid particles, wherein at least 50% of the solid particles are less than 1.5 mm in one or more size dimensions, and C5 monosaccharides and/or disaccharides in a yield that is at least 50% of a theoretical maximum, wherein pretreating comprises: hydration of the biomass composition in a non-neutral pH aqueous medium comprising one or more acids to produce a hydrated biomass composition, 
(i) hidrataciju pripravka biomase u vodenom mediju ne-neutralnog pH koji sadrži jednu ili više kiselina da se proizvede hidratizirani pripravak biomase, (ii) mehaničko smanjenje veličine hidratiziranog pripravka biomase da se dobiju krute čestice, i (ili) zagrijavanje hidratiziranog pripravka biomase u vremenu dostatnom da se dobije prethodno obrađeni pripravak biomase koji sadrži C5 monosaharide i/ili disaharide uz prinos koji je barem 50% teorijskog maksimuma; i
incubating said liquid with one or more glucose fermenting microorganisms capable of fermenting glucose to an organic acid; or incubating said liquid with an enzyme or a mixture of enzymes capable of catalyzing conversion of glucose to form an organic acid; and 
inkubiranje navedene tekućine s jednim ili više mikroorganizama koji fermentiraju glukozu koji su sposobni fermentirati glukozu u organsku kiselinu; ili inkubiranje navedene tekućine s enzimom ili smjesom enzima sposobnima katalizirati pretvaranje glukoze tako da nastane organska kiselina; i
In another embodiment of the invention, the glycosylated polypeptide is selected from the group comprising a polypeptide having a primary amino acid sequence of a human glycosylated polypeptide, a primary amino acid sequence of a non-human glycosylated polypeptide, a primary amino acid sequence of an antibody or an active fragment thereof, and/or a primary amino acid sequence of a non-mammalian glycosylated polypeptide. 
Metoda u skladu sa patentnim zahtjevom 1, gdje glikozilirani polipeptid je odabran iz grupe koja sadrži polipeptid koji ima primarnu aminokiselinsku sekvencu humanog glikoziliranog polipeptida, primarnu aminokiselinsku sekvencu ne-humanog glikoziliranog polipeptida, primarnu aminokiselinsku sekvencu antitijela ili njegovog aktivnog dijela, i/ili primarnu aminokiselinsku sekvencu glikoziliranog polipeptida koji nije porijeklom iz sisavaca.
In one embodiment, at the opposite end, i.e. at the inlet 102, size reducing means may be provided for reducing the size of the solid component of liposuctioned fat 3, particularly cell macroagglomerates, to smaller cell agglomerates, i.e. having a size equal to or smaller than a given value, which means consist of at least one series of parallel or intersecting sheets or cutting wires made of sterile material, e.g. metal, to form at least one size reducing net, through which the liposuctioned material is passed before entering the washing chamber 101 of the washing and separating container 1. 
Uređaj kao što je naveden u jednom ili više patentnih zahtjeva, naznačen time da su sredstva (3) za smanjivanje veličine osigurana za smanjivanje veličine čvrste komponente masti (3) dobivene liposukcijom posebno staničnih makroaglomerata na manje stanične makroaglomerate, tj. koji imaju veličinu jednaku ili manju od zadane vrijednosti, pri čemu se sredstva sastoje od najmanje jedne serije paralelnih ili presjecajućih ploča ili žica za sječenje, za formiranje najmanje jedne mreže za smanjenje veličine, kroz koju materijal dobiven liposukcijom prolazi prije nego što uđe u komoru za pranje (101) kontejnera za pranje i odvajanje (1).
a first collection tank (31) connected with a discharge of grey water from the kitchen and the galley; 
prvog sabirnog spremnika (31), spojenog s ispustom sive vode iz kuhinje i brodske kuhinje;
Fig. 9 shows the state of the second embodiment in which the front surface 23 of the bell member 9 is in sealing engagement with the sealing member 8 of the capsule 1. 
Slika 9 prikazuje položaj drugog ostvarenja u kojemu je prednja površina 23 zvonastog elementa 9 u položaju kada brtva zahvaća s element za nepropusno zatvaranje 8 čahure 1.
In these embodiments, the inner layer additionally comprises at least one additive selected from a buffer agent and a base. 
Formulacija lijeka s odloženim otpuštanjem sukladno patentnom zahtjevu 1 ili patentnom zahtjevu 2, naznačeno time, da unutarnji sloj sadrži najmanje jedno pufersko sredstvo i najmanje jednu bazu.
Sulbactam is present as sodium salt thereof. 
sulbaktam je prisutan u vidu svoje natrijeve soli.
an optionally buffered aqueous solution of an antibody, optionally modified by means of a modifying agent, and a solution of a cryptophycin payload of formula (II) as defined in one of claims 14 to 21, the chemical group RCG1 of the cryptophycin payloadof formula (II) being reactive towards the chemical groups RCG2 present on the antibody especially towards the amino groups present on antibodies, the said chemical groups RCG2 having been introduced, where appropriate, by the modifying agent, so as to attach the cryptophycin payload of formula (II) to the antibody by formation of a covalent bond; 
- po izboru puferirane vodene otopine protutijela, proizvoljno modificirane pomoću sredstva za modificiranje, i - < otopine korisnog dijela kriptoficina s formulom (Il) kako je definirano u jednom od zahtjeva 14 do kemijska skupina RCGI1 korisnog dijela kriptoficina s formulom (II) je reaktivna prema kemijskim skupinama _ RCG2 prisutnima na protutijelu, posebno prema amino skupinama prisutnim na protutijelima, pri čemu su navedene kemijske skupine RCG2, gdje je prikladno, uvedene, pomoću sredstva za modificiranje, tako da se korisni dio kriptoficina s formulom (Il) veže na protutijelo stvaranjem kovalentne veze;
The pharmaceutical composition according to claim 16, which is to be administered intradermally, in particular by tattooing. 
Farmaceutski sastav prema patentnom zahtjevu 4, gdje se farmaceutski sastav primjenjuje intradermalno tetoviranjem, mikroiglom i/ili flasterima sa mikroiglama.
The method according to claim 1, wherein said condition is selected from the group consisting of atherosclerosis, inflammation of the eye including uveitis, iritis, iridocyclitis, alcoholic hepatitis, allograft transplantation, xenograft transplantation, glomerulonephritis, reperfusion injury and acute inflammatory conditions following myocardial infarction and stroke. 
Farmaceutski pripravak za uporabu prema zahtjevu 18, gdje je navedena upalna bolest izabrana iz skupine koja se sastoji od ateroskleroze, upale oka uključujući uveitis, iritis, iridociklitis, alkoholnog hepatitisa, transplantacije alografta, transplantacije ksenografta, glomerulonefritisa, reperfuzijske ozljede i akutnih upalnih stanja nakon infarkta miokarda i moždanog udara.
A processing method executed by a base station device which transmits timing deviation information to a mobile station device for the mobile station device to manage an uplink synchronous status by using a timer so that the uplink synchronous status is sustained until the timer expires after the timer is reset on receiving the timing deviation information, wherein the base station device receives a random access preamble whose preamble ID was randomly selected by the mobile station device and sent from the mobile station device; and sends to the mobile station device a random access response corresponding to the random access preamble, the random access response comprising timing deviation information used for the mobile station device to discard in an uplink synchronous status. 
odbacivanje, u sinkronom statusu uzlazne veze, informacije o odstupanju vremena sadržane u primljenom odgovoru slučajnog pristupa (S02). Postupak obrade prema zahtjevu 5, naznačen time da je uređaj mobilne stanice (50) nadalje prilagođen da upravlja sinkronim statusom uzlazne veze korištenjem vremenskog brojača tako da se sinkroni status uzlazne veze održava sve dok istekne vremenski brojač nakon što se vremenski brojač resetira, te pri čemu korak odbacivanja sadrži, u sinkronom statusu uzlazne veze, ne resetiranje vremenskog brojača na osnovi informacije o odstupanju vremena sadržane u primljenom odgovoru slučajnog pristupa (S02).
Effect of Treatment in the Active Avoidance Test. 
Učinak tretmana u testu aktivnog izbjegavanja.
The method according to one of claim 1 - 6 or 7 - 10, comprising a further stage of processing the non-magnetic residues to recover the copper content in the non-magnetic residue and/or recover precious metals contained in the non-magnetic residue in particular selected from gold, silver, lead, tin, platinum, palladium, rhodium, ruthenium, iridium and/or osmium. 
Postupak sukladno jednom od patentnih zahtjeva 1-8, naznačeno time da obuhvaća naknadni korak obrade ne magnetskih ostataka za oporavak sadržaja bakra u ne magnetskom ostatku i/ili oporavak plemenitih metala sadržanih u ne magnetskim ostacima posebno odabranom od zlata, srebra, olova, kositra, platine, paladija, rodija, rutenija, iridija i/ili osmija.
An isolated peptide antagonist of Kv1.3 having an amino acid sequence comprising an amino acid sequence which is at least 84% identical to SEQ ID NO: 1, further comprising a substitution of glycine to isoleucine at position 10 (G10I). 
Izolirani peptidni antagonist Kv1.3 naznačen time da ima sekvencu aminokiselina koja sadrži sekvencu aminokiselina koja je barem 84% identična sa SEQ ID NO: 1, koja nadalje ima supstituciju glicina s izoleucinom u položaju 10 (G10D.
The method of claims 18 to 19, wherein the liquid coating formulation used to form an absorptive layer and/or a topcoat has a solid content of 10 to 80 wt.-%, preferably of 30 to 60 wt.-%, and more preferably of 45 to 55 wt.-% based on the total weight of the formulation. 
Postupak prema zahtjevima 17 ili 18, pri čemu tekući oblik premaza koji se koristi za dobivanje apsorpcijskog sloja i/ili završnog premaza ima sadržaj krutih tvari od 10 do 80 tež.-%, poželjno od 30 do 60 tež.-%, i poželjnije od 45 do 55 tež.-% u odnosu na ukupnu težinu tekućeg oblika.
The compound of claim 24, wherein the Ar2 phenyl is substituted with a -(C1-C6) alkyl group, with a -CF3 group, with -Cl, with -Br, with -F, with -I or with -OCF3. 
. Spoj prema zahtjevu 24, naznačen time da Ar, fenil je supstituiran s (C;-C4) alkilnom skupinom, s -CF: skupinom,
A process for preparing a compound according to formula (1), or salt thereof, wherein R1 is hydrogen or a nitrogen protecting group, said process comprising reducing a compound according to formula (13), or salt thereof, wherein R1 is hydrogen or a nitrogen protecting group, to obtain the compound according formula (1), or salt thereof. 
Postupak za proizvodnju spoja u skladu sa sljedećom formulom (1) ili njegove soli: gdje RI je vodikova ili dušikova zaštitna skupina, naznačena time, da navedeni postupak obuhvaća redukciju spoja u skladu sa sljedećom formulom (13) ili njegove soli: no gdje RI je vodikova ili dušikova zaštitna skupina, kako bi se dobio spoj u skladu s formulom (1) ili njegova sol.
The pharmaceutical composition of claim 8, wherein the GLP-1 R agonist is selected from GLP-1 (7-37), GLP-1 (7-36)amide, exendin-4, liraglutide, CJC-1131, albugon, albiglutide, exenatide, exenatide-LAR, oxyntomodulin, lixisenatide, geniproside, AVE-0010 (SEQ ID NO: 9), a short peptide with GLP-1 R agonistic activity and/or a small organic compound with GLP-1 R agonistic activity. 
Farmaceutski pripravak za uporabu prema zahtjevu 8, naznačen time što je agonist GLP-1 R odabran od GLP-1 (7-37), GLP-1 (7-36)amida, eksendina-4, liraglutida, CIC-1131, albugona, albiglutida, eksenatida, eksenatida-LAR, oksintomodulina, liksisenatida, geniprozida, kratkog peptida s aktivnošću agonista GLP-IR i/ili malog organskog spoja s aktivnošću agonista GLP-1R.
and metazachlor, and, if desired, 
B) kvinmerak; i, ako je poželjno,
The assembly of claim 11, further comprising: a radio frequency identification device adapted to communicate with a radio frequency receiver, wherein the radio frequency identification device is adapted to communicate to the radio frequency receiver identifying information of the contents of the portable gas canister that is attachable to the spring biased needle valve. 
Indeksirani uređaj za ograničavanje sadržaja lijeka (24) prema bilo kojem od zahtjeva 1-5, naznačen time da nadalje sadrži radio frekvencijski identifikacijski uređaj (50) prilagođen za komuniciranje s radio frekvencijskim prijemnikom.
The solid oral extended release pharmaceutical dosage form of claim 6, wherein the extended release matrix formulation has been stored at 40 °C and 75 % relative humidity (RH). 
Farmaceutski oblik za doziranje s produljenim otpuštanjem u krutom obliku za oralnu upotrebu prema zahtjevu 4, naznačen time da je formulacija matrice s produljenim otpuštanjem bila uskladišten pri 40°C i 75% relativne vlažnosti zraka (RH).
According to a further embodiment, an apparatus may further comprise a flatness measuring device arranged to provide a signal indicative of flatness of the metal strip after it passes from the roll. 
Uređaj prema zahtjevu 1, naznačen time, da nadalje sadrži sredstvo za mjerenje plosnatosti (9) namješteno za davanje signala koji pokazuje plosnatost metalne trake (2) nakon što ona prolazi iz valjka (3).
the alkyl, alkenyl, and alkynyl portion of such substituents optionally is substituted with one or more substituents independently selected from the group consisting of carboxy, halo, oxo, amino, alkyloxycarbonyl, alkylcarbonyloxy, hydroxy, alkyloxy, carbocyclyl, heterocyclyl, and cyano, wherein: 
alkil, alkenil i alkinil dio od takvih supstituenata je opcijski supstituiran s jednim ili više supstituenata neovisno odabranima iz skupine koju sačinjavaju karboksi, halo, okso, amino, alkiloksikarbonil, alkilkarboniloksi, hidroksi, alkiloksi, karbociklil, heterociklil i cijano, pri čemu:
These irregularities may further be produced by adding material to the surface or by taking off material from the surface of the body. 
Takve se nepravilnosti mogu dodatno proizvesti dodavanjem materijala na površinu ili skidanjem materijala s površine tijela.
A pharmaceutical composition, characterized in comprising the compound, the pharmaceutically acceptable salt thereof or the stereoisomer thereof according to any one of claims 1-9 and one or more therapeutically active substances selected from TNF-a inhibitors, COX-1/COX-2 inhibitors, COX-2 inhibitors, glucocorticoids, inactivated antibodies for interleukin, regulators for chemotactic factor receptors, antagonists for histamine H1 receptors/antihistamines, antagonists for leukotriene D4 receptors, leukotriene antagonists, LTD4 antagonists, VLA-4 antagonists, corticosteroids, corticosteroids analogues, B2-agonists, theophylline, leukotriene biosynthetic inhibitors, epoxidase-2 inhibitors, phosphodiesterase type IV inhibitors, opioids analgesics, anticoagulants, B-blocking agents, B-adrenergic agonists, angiotensin converting enzyme inhibitors or HMG-CoA reducase inhibitors. 
Farmaceutski pripravak, naznačen time što sadrži spoj ili njegovu farmaceutski prihvatljivu sol prema bilo kojem od zahtjeva 1-4 i jednu ili više terapeutski aktivnih tvari odabranih iz skupa koji čine inhibitori TNF-a, inhibitori COX-1/COX-2, inhibitori COX-2, glukokortikoidi, inaktivirana protutijela za interleukin, regulatori za receptore kemotaktičkog faktora, antagonisti histaminskih HI receptora/antihistaminika, antagonisti leukotriena, antagonisti LTD4, antagonisti VLA-4, kortikosteroidi, analozi kortikosteroida, B2-agonisti, teofilin, biosintetski inhibitori leukotriena, inhibitori fosfodiesteraze tipa IV, opioidni analgetici, antikoagulanti, B B-blokatori, B-adrenergički agonisti, inhibitori angiotenzin konvertirajućeg enzima ili inhibitori HMG-CoA reduktaze.
An antibody which specifically binds to a polypeptide consisting of the amino acid sequence represented by SEQ ID NO: 8 in the sequence listing, wherein the antibody has the amino acid sequences represented by SEQ ID NOs: 71, 73, and 75 in the sequence listing, or amino acid sequences having deletion, substitution, or addition of one or more amino acids in the amino acid sequences, as complementarity determining regions in the heavy chain variable region and has the amino acid sequences represented by SEQ ID NOs: 77, 79, and 81 in the sequence listing, or amino acid sequences having deletion, substitution, or addition of one or more amino acids in the amino acid sequences, as complementarity determining regions in the light chain variable region. 
Antitijelo u skladu sa patentnim zahtjevom 1 gdje antitijelo ima aminokiselinske sekvence predstavljene pomoću SEQ ID NOs: 71, 73, 75 u listi sekvenci kao regione koji određuju komplementarnost u varijabilnom regionu teškog lanca i ima aminokiselinske sekvence predstavljene pomoću SEQ ID NOs: 77, 79, i 81 u listi sekvenci kao regione koji određuju komplementarnost u varijabilnom regionu lakog lanca. Antitijelo u skladu sa patentnim zahtjevom 12, gdje antitijelo ima aminokiselinske sekvence predstavljene pomoću SEQ ID NOS: 141 kao CDRH1, 143 kao CDRH2 i 145 kao CDRH3 i ima aminokiselinsku sekvencu predstavljenu pomoću SEQ ID NOS: 125 kao CDRL1, 127 kao CDRL2 i 129 kao CDRL3 u listi sekvenci.
Pharmaceutical composition according to claim 37 for use as pro-apoptotic agents. Pharmaceutical composition for use according to claim 38 for the treatment of cancers and of auto-immune and immune system diseases. 
Farmaceutski pripravak za uporabu u skladu s patentnim zahtjevom 38, naznačen time, da je za liječenje karcinoma i auto-imunih bolesti kao i bolesti imuno-sustava.
moving the rotating container through the vacuum chamber from the input end to a discharge end thereof while applying microwave radiation to the tumbling organic material to dehydrate the organic material; and 
(d) pokretanja posude koja rotira kroz vakuumsku komoru od ulaznog kraja (30) do kraja (34) za pražnjenje iste dok se primjenjuje mikrovalno zračenje da se dehidrira organski materijal; i